Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus

Characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo

Tomohiro Chiba, Marina Yamada, Yuichi Hashimoto, Maiko Sato, Jumpei Sasabe, Yoshiko Kita, Kenzo Terashita, Sadakazu Aiso, Ikuo Nishimoto, Masaaki Matsuoka

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common cause of dementia. Humanin (HN) is a short bioactive peptide abolishing neuronal cell death induced by various familial AD (FAD)-causative genes and amyloid-β (Aβ) in vitro. It has been shown that HN suppresses memory impairment of mice induced by intracerebroventricular administration of Aβ. To potentiate the neuroprotective effect of HN, we synthesized a hybrid peptide named Colivelin composed of activity-dependent neurotrophic factor (ADNF) C-terminally fused to AGA-(C8R)HNG17, a potent HN derivative. Colivelin completely suppresses death induced by overexpressed FAD-causative genes and Aβ1-43 at a concentration of 100 fM, whereas AGA-(C8R)HNG17 does so at a concentration of 10 pM. Colivelin-induced neuroprotection has been confirmed to occur via two neuroprotective pathways: one mediated by Ca2+/calmodulin-dependent protein kinase IV, triggered by ADNF, and one mediated by signal transducer and activator of transcription 3, triggered by HN. In vivo animal studies have further indicated that intracerebroventricular administration of Colivelin not only completely suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, but also it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42. In addition, intraperitoneally administered Colivelin suppresses memory impairment caused by a muscarinic acetylcholine receptor antagonist, 3-quinuclidinyl benzilate, indicating that a substantial portion of intraperitoneally administered Colivelin passes through the blood-brain barrier and suppresses functional memory deficit. Thus, Colivelin might serve as a novel drug candidate for treatment of AD.

Original languageEnglish
Pages (from-to)10252-10261
Number of pages10
JournalJournal of Neuroscience
Volume25
Issue number44
DOIs
Publication statusPublished - 2005 Nov 2
Externally publishedYes

Keywords

  • ADNF
  • Alzheimer's disease
  • APP
  • Colivelin
  • Humanin

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus : Characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. / Chiba, Tomohiro; Yamada, Marina; Hashimoto, Yuichi; Sato, Maiko; Sasabe, Jumpei; Kita, Yoshiko; Terashita, Kenzo; Aiso, Sadakazu; Nishimoto, Ikuo; Matsuoka, Masaaki.

In: Journal of Neuroscience, Vol. 25, No. 44, 02.11.2005, p. 10252-10261.

Research output: Contribution to journalArticle

Chiba, Tomohiro ; Yamada, Marina ; Hashimoto, Yuichi ; Sato, Maiko ; Sasabe, Jumpei ; Kita, Yoshiko ; Terashita, Kenzo ; Aiso, Sadakazu ; Nishimoto, Ikuo ; Matsuoka, Masaaki. / Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus : Characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. In: Journal of Neuroscience. 2005 ; Vol. 25, No. 44. pp. 10252-10261.
@article{c3729778a4f949deb964aee30107060b,
title = "Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: Characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo",
abstract = "Alzheimer's disease (AD) is the most common cause of dementia. Humanin (HN) is a short bioactive peptide abolishing neuronal cell death induced by various familial AD (FAD)-causative genes and amyloid-β (Aβ) in vitro. It has been shown that HN suppresses memory impairment of mice induced by intracerebroventricular administration of Aβ. To potentiate the neuroprotective effect of HN, we synthesized a hybrid peptide named Colivelin composed of activity-dependent neurotrophic factor (ADNF) C-terminally fused to AGA-(C8R)HNG17, a potent HN derivative. Colivelin completely suppresses death induced by overexpressed FAD-causative genes and Aβ1-43 at a concentration of 100 fM, whereas AGA-(C8R)HNG17 does so at a concentration of 10 pM. Colivelin-induced neuroprotection has been confirmed to occur via two neuroprotective pathways: one mediated by Ca2+/calmodulin-dependent protein kinase IV, triggered by ADNF, and one mediated by signal transducer and activator of transcription 3, triggered by HN. In vivo animal studies have further indicated that intracerebroventricular administration of Colivelin not only completely suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, but also it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42. In addition, intraperitoneally administered Colivelin suppresses memory impairment caused by a muscarinic acetylcholine receptor antagonist, 3-quinuclidinyl benzilate, indicating that a substantial portion of intraperitoneally administered Colivelin passes through the blood-brain barrier and suppresses functional memory deficit. Thus, Colivelin might serve as a novel drug candidate for treatment of AD.",
keywords = "Aβ, ADNF, Alzheimer's disease, APP, Colivelin, Humanin",
author = "Tomohiro Chiba and Marina Yamada and Yuichi Hashimoto and Maiko Sato and Jumpei Sasabe and Yoshiko Kita and Kenzo Terashita and Sadakazu Aiso and Ikuo Nishimoto and Masaaki Matsuoka",
year = "2005",
month = "11",
day = "2",
doi = "10.1523/JNEUROSCI.3348-05.2005",
language = "English",
volume = "25",
pages = "10252--10261",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "44",

}

TY - JOUR

T1 - Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus

T2 - Characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo

AU - Chiba, Tomohiro

AU - Yamada, Marina

AU - Hashimoto, Yuichi

AU - Sato, Maiko

AU - Sasabe, Jumpei

AU - Kita, Yoshiko

AU - Terashita, Kenzo

AU - Aiso, Sadakazu

AU - Nishimoto, Ikuo

AU - Matsuoka, Masaaki

PY - 2005/11/2

Y1 - 2005/11/2

N2 - Alzheimer's disease (AD) is the most common cause of dementia. Humanin (HN) is a short bioactive peptide abolishing neuronal cell death induced by various familial AD (FAD)-causative genes and amyloid-β (Aβ) in vitro. It has been shown that HN suppresses memory impairment of mice induced by intracerebroventricular administration of Aβ. To potentiate the neuroprotective effect of HN, we synthesized a hybrid peptide named Colivelin composed of activity-dependent neurotrophic factor (ADNF) C-terminally fused to AGA-(C8R)HNG17, a potent HN derivative. Colivelin completely suppresses death induced by overexpressed FAD-causative genes and Aβ1-43 at a concentration of 100 fM, whereas AGA-(C8R)HNG17 does so at a concentration of 10 pM. Colivelin-induced neuroprotection has been confirmed to occur via two neuroprotective pathways: one mediated by Ca2+/calmodulin-dependent protein kinase IV, triggered by ADNF, and one mediated by signal transducer and activator of transcription 3, triggered by HN. In vivo animal studies have further indicated that intracerebroventricular administration of Colivelin not only completely suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, but also it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42. In addition, intraperitoneally administered Colivelin suppresses memory impairment caused by a muscarinic acetylcholine receptor antagonist, 3-quinuclidinyl benzilate, indicating that a substantial portion of intraperitoneally administered Colivelin passes through the blood-brain barrier and suppresses functional memory deficit. Thus, Colivelin might serve as a novel drug candidate for treatment of AD.

AB - Alzheimer's disease (AD) is the most common cause of dementia. Humanin (HN) is a short bioactive peptide abolishing neuronal cell death induced by various familial AD (FAD)-causative genes and amyloid-β (Aβ) in vitro. It has been shown that HN suppresses memory impairment of mice induced by intracerebroventricular administration of Aβ. To potentiate the neuroprotective effect of HN, we synthesized a hybrid peptide named Colivelin composed of activity-dependent neurotrophic factor (ADNF) C-terminally fused to AGA-(C8R)HNG17, a potent HN derivative. Colivelin completely suppresses death induced by overexpressed FAD-causative genes and Aβ1-43 at a concentration of 100 fM, whereas AGA-(C8R)HNG17 does so at a concentration of 10 pM. Colivelin-induced neuroprotection has been confirmed to occur via two neuroprotective pathways: one mediated by Ca2+/calmodulin-dependent protein kinase IV, triggered by ADNF, and one mediated by signal transducer and activator of transcription 3, triggered by HN. In vivo animal studies have further indicated that intracerebroventricular administration of Colivelin not only completely suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, but also it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42. In addition, intraperitoneally administered Colivelin suppresses memory impairment caused by a muscarinic acetylcholine receptor antagonist, 3-quinuclidinyl benzilate, indicating that a substantial portion of intraperitoneally administered Colivelin passes through the blood-brain barrier and suppresses functional memory deficit. Thus, Colivelin might serve as a novel drug candidate for treatment of AD.

KW - Aβ

KW - ADNF

KW - Alzheimer's disease

KW - APP

KW - Colivelin

KW - Humanin

UR - http://www.scopus.com/inward/record.url?scp=27744563035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744563035&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.3348-05.2005

DO - 10.1523/JNEUROSCI.3348-05.2005

M3 - Article

VL - 25

SP - 10252

EP - 10261

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 44

ER -